HRP20160495T1 - Morfolinilbenzotriazini za uporabu u terapiji raka - Google Patents
Morfolinilbenzotriazini za uporabu u terapiji raka Download PDFInfo
- Publication number
- HRP20160495T1 HRP20160495T1 HRP20160495TT HRP20160495T HRP20160495T1 HR P20160495 T1 HRP20160495 T1 HR P20160495T1 HR P20160495T T HRP20160495T T HR P20160495TT HR P20160495 T HRP20160495 T HR P20160495T HR P20160495 T1 HRP20160495 T1 HR P20160495T1
- Authority
- HR
- Croatia
- Prior art keywords
- atoms
- hal
- image
- denotes
- tautomers
- Prior art date
Links
- JHIMBAPIOFMFBP-UHFFFAOYSA-N 4-(1,2,3-benzotriazin-4-yl)morpholine Chemical compound C1COCCN1C1=NN=NC2=CC=CC=C12 JHIMBAPIOFMFBP-UHFFFAOYSA-N 0.000 title 1
- 238000011275 oncology therapy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 11
- 239000000203 mixture Substances 0.000 claims 9
- 125000004432 carbon atom Chemical group C* 0.000 claims 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 4
- 125000004430 oxygen atom Chemical group O* 0.000 claims 4
- 125000004434 sulfur atom Chemical group 0.000 claims 4
- 206010028980 Neoplasm Diseases 0.000 claims 3
- 125000000217 alkyl group Chemical group 0.000 claims 3
- 239000002246 antineoplastic agent Substances 0.000 claims 3
- 125000002950 monocyclic group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 102100030011 Endoribonuclease Human genes 0.000 claims 1
- 101710199605 Endoribonuclease Proteins 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 101710113029 Serine/threonine-protein kinase Proteins 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 230000005865 ionizing radiation Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000001959 radiotherapy Methods 0.000 claims 1
- 230000001235 sensitizing effect Effects 0.000 claims 1
- 238000002560 therapeutic procedure Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
- A61N5/00—Radiation therapy
- A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
- C07D253/08—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/0803—Compounds with Si-C or Si-Si linkages
- C07F7/081—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
- C07F7/0812—Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/10—Compounds having one or more C—Si linkages containing nitrogen having a Si-N linkage
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic Table
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pathology (AREA)
- Radiology & Medical Imaging (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102011118830A DE102011118830A1 (de) | 2011-11-18 | 2011-11-18 | Morpholinylbenzotriazine |
PCT/EP2012/004542 WO2013072015A1 (de) | 2011-11-18 | 2012-10-30 | Morpholinylbenzotriazine zur anwendung in der krebstherapie |
EP12783121.2A EP2780332B1 (de) | 2011-11-18 | 2012-10-30 | Morpholinylbenzotriazine zur anwendung in der krebstherapie |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20160495T1 true HRP20160495T1 (hr) | 2016-06-03 |
Family
ID=47143824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20160495TT HRP20160495T1 (hr) | 2011-11-18 | 2016-05-09 | Morfolinilbenzotriazini za uporabu u terapiji raka |
Country Status (24)
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PT2841428T (pt) | 2012-04-24 | 2018-11-29 | Vertex Pharma | Inibidores de adn-pk |
EP3985003B1 (en) | 2013-03-12 | 2023-08-09 | Vertex Pharmaceuticals Incorporated | Dna-pk inhibitors |
DE102013008118A1 (de) | 2013-05-11 | 2014-11-13 | Merck Patent Gmbh | Arylchinazoline |
CN105814036B (zh) | 2013-10-17 | 2018-10-26 | 沃泰克斯药物股份有限公司 | 作为dna-pk抑制剂的共晶 |
KR20190062485A (ko) | 2016-09-27 | 2019-06-05 | 버텍스 파마슈티칼스 인코포레이티드 | Dna-손상제 및 dna-pk 저해제의 조합을 사용한 암 치료 방법 |
CN107793373B (zh) * | 2017-10-31 | 2019-09-17 | 广西师范大学 | 2-取代苯并三嗪酮衍生物及其制备方法 |
EA202091708A1 (ru) * | 2018-01-17 | 2020-11-10 | Вертекс Фармасьютикалз Инкорпорейтед | Ингибиторы днк-пк |
WO2021083936A1 (en) | 2019-11-01 | 2021-05-06 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic compounds |
WO2022268648A1 (en) | 2021-06-24 | 2022-12-29 | Syngenta Crop Protection Ag | 2-[3-[1 [(quinazolin-4-yl)amino]ethyl]pyrazin-2-yl]thiazole-5-carbonitrile derivatives and similar compounds as pesticides |
WO2023247360A1 (en) | 2022-06-21 | 2023-12-28 | Syngenta Crop Protection Ag | Pesticidally active fused bicyclic heteroaromatic compounds |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE9190155U1 (de) | 1990-11-06 | 1993-10-07 | Pfizer Inc., New York, N.Y. | Chinazolinderivate zur Steigerung der Antitumoraktivität |
AU4972900A (en) | 1999-04-08 | 2000-11-14 | Arch Development Corporation | Use of anti-vegf antibody to enhance radiation in cancer therapy |
AU2001288432A1 (en) * | 2000-09-01 | 2002-03-22 | Icos Corporation | Materials and methods to potentiate cancer treatment |
US7291733B2 (en) * | 2003-10-10 | 2007-11-06 | Boehringer Ingelheim Pharmaceuticals, Inc. | Substituted tricyclic heterocycles and their uses |
CN101230045B (zh) * | 2008-02-14 | 2013-04-10 | 沈阳药科大学 | 芳环并三嗪类衍生物及其应用 |
SG183855A1 (en) * | 2010-03-16 | 2012-10-30 | Merck Patent Gmbh | Morpholinylquinazolines |
-
2011
- 2011-11-18 DE DE102011118830A patent/DE102011118830A1/de not_active Withdrawn
-
2012
- 2012-10-30 BR BR112014011805A patent/BR112014011805A2/pt not_active Application Discontinuation
- 2012-10-30 KR KR1020147016518A patent/KR20140097391A/ko not_active Application Discontinuation
- 2012-10-30 CA CA2856103A patent/CA2856103C/en active Active
- 2012-10-30 MX MX2014005838A patent/MX2014005838A/es not_active Application Discontinuation
- 2012-10-30 RS RS20160351A patent/RS54768B1/sr unknown
- 2012-10-30 PL PL12783121T patent/PL2780332T3/pl unknown
- 2012-10-30 EA EA201400595A patent/EA201400595A1/ru unknown
- 2012-10-30 IN IN1287KON2014 patent/IN2014KN01287A/en unknown
- 2012-10-30 SI SI201230559A patent/SI2780332T1/sl unknown
- 2012-10-30 ES ES12783121.2T patent/ES2572605T3/es active Active
- 2012-10-30 EP EP12783121.2A patent/EP2780332B1/de active Active
- 2012-10-30 DK DK12783121.2T patent/DK2780332T3/en active
- 2012-10-30 JP JP2014541555A patent/JP6096792B2/ja active Active
- 2012-10-30 AU AU2012339196A patent/AU2012339196B2/en active Active
- 2012-10-30 SG SG11201402206YA patent/SG11201402206YA/en unknown
- 2012-10-30 WO PCT/EP2012/004542 patent/WO2013072015A1/de active Application Filing
- 2012-10-30 HU HUE12783121A patent/HUE027577T2/en unknown
- 2012-10-30 US US14/351,773 patent/US9187469B2/en active Active
- 2012-10-30 CN CN201280056504.4A patent/CN103930408B/zh active Active
-
2014
- 2014-05-12 IL IL232577A patent/IL232577A/en active IP Right Grant
- 2014-06-17 ZA ZA2014/04438A patent/ZA201404438B/en unknown
-
2015
- 2015-01-12 HK HK15100269.7A patent/HK1199875A1/xx unknown
-
2016
- 2016-05-09 HR HRP20160495TT patent/HRP20160495T1/hr unknown
Also Published As
Publication number | Publication date |
---|---|
HUE027577T2 (en) | 2016-10-28 |
MX2014005838A (es) | 2014-07-30 |
DK2780332T3 (en) | 2016-05-30 |
JP6096792B2 (ja) | 2017-03-15 |
RS54768B1 (sr) | 2016-10-31 |
ES2572605T3 (es) | 2016-06-01 |
CN103930408A (zh) | 2014-07-16 |
ZA201404438B (en) | 2015-12-23 |
SG11201402206YA (en) | 2014-11-27 |
KR20140097391A (ko) | 2014-08-06 |
AU2012339196B2 (en) | 2017-04-27 |
US9187469B2 (en) | 2015-11-17 |
JP2015502926A (ja) | 2015-01-29 |
HK1199875A1 (en) | 2015-07-24 |
IN2014KN01287A (US20070167479A1-20070719-C00034.png) | 2015-10-16 |
CA2856103A1 (en) | 2013-05-23 |
EP2780332A1 (de) | 2014-09-24 |
PL2780332T3 (pl) | 2016-07-29 |
CN103930408B (zh) | 2016-09-07 |
EP2780332B1 (de) | 2016-02-24 |
DE102011118830A1 (de) | 2013-05-23 |
IL232577A0 (en) | 2014-06-30 |
WO2013072015A1 (de) | 2013-05-23 |
EA201400595A1 (ru) | 2014-11-28 |
US20140275072A1 (en) | 2014-09-18 |
SI2780332T1 (sl) | 2016-06-30 |
AU2012339196A1 (en) | 2014-07-03 |
CA2856103C (en) | 2020-08-25 |
BR112014011805A2 (pt) | 2017-05-16 |
IL232577A (en) | 2017-05-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20160495T1 (hr) | Morfolinilbenzotriazini za uporabu u terapiji raka | |
HRP20150489T1 (hr) | Imidazo[4,5-c]kinolini kao inhibitori dna-pk | |
JP6789239B2 (ja) | Krasの縮合三環系インヒビターおよびその使用の方法 | |
JP6862495B2 (ja) | Jak及びpi3k阻害剤併用によるb細胞悪性腫瘍の処置 | |
HRP20150030T1 (hr) | Derivati pirazolokinolina kao inhibitori dna-pk | |
JP2021098721A (ja) | 置換キナゾリン化合物およびその使用方法 | |
MX2009009843A (es) | Compuestos espiro sustituidos como inhibidores de la angiogenesis. | |
EA201201289A1 (ru) | Морфолинилхиназолины | |
NZ630457A (en) | Compounds useful as inhibitors of atr kinase | |
JP2021107465A (ja) | N−(シアノメチル)−4−(2−(4−モルホリノフェニルアミノ)ピリミジン−4−イル)ベンズアミド塩酸塩 | |
HRP20140814T1 (hr) | Inhibitori jak2 i njihova uporaba za lijeäśenje mijeloproliferativnih bolesti i karcinoma | |
HRP20220886T1 (hr) | Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću | |
AR073551A1 (es) | Pirimidinas macrociclicas como inhibidores de proteina cinasa | |
JP2014503567A5 (US20070167479A1-20070719-C00034.png) | ||
JP2013529196A5 (US20070167479A1-20070719-C00034.png) | ||
WO2010021918A8 (en) | Compounds as kinase inhibitors | |
RU2758669C2 (ru) | Способ лечения рака с применением сочетания днк-поражающих агентов и ингибиторов днк-пк | |
PE20230372A1 (es) | Triazolopirimidinas como inhibidores de a2a/a2b | |
HRP20211801T1 (hr) | Derivati kinolin-2-ona | |
JP2015503627A (ja) | ジヒドロピロロ[1,2−c]イミダゾリルアルドステロンシンターゼまたはアロマターゼ阻害薬の新たな形態および塩 | |
EP2906564A1 (en) | Treating brain cancer using agelastatin a (aa) and analogues thereof | |
CA3201605A1 (en) | Alk-5 inhibitors and uses thereof | |
HRP20231276T1 (hr) | Inhibitor egfr-a za liječenje raka | |
SI2864328T1 (en) | Pharmaceutically active compounds | |
US20240197729A1 (en) | ALK-5 Inhibitors and Uses Thereof |